Meet Fanny
Fanny Kling is a Regulatory and Pre-clinical leader with expertise in Drug Development and Regulatory Science. She holds a Master's degree in Bioengineering and Health from AgroParisTech (Paris Institute of Life and Environmental Sciences, France), specialized in Toxicology and Ecotoxicology. With four years as a non-clinical and early clinical regulatory consultant at Voisin Consulting Life Science, she contributed to various development programs, including RNA therapies, small molecules, and ATMPs. She actively prepared and participated in regulatory interactions (FDA & EMA), with proficiency in crafting regulatory documents and development plans, from early preclinical phases to the preparation of now approved MAA/NDA submissions.
At HAYA Therapeutics, Fanny manages preclinical development activities, including efficacy, pharmacokinetics and toxicology studies, ensuring efficient data management, and the strategic planning and execution of regulatory strategies.
